ZA Miner Launches New Dogecoin Cloud Mining Contract Amid Crypto Market Uncertainty
LONDON, June 20, 2025 (GLOBE NEWSWIRE) —
As the crypto market rides another wave of volatility, both seasoned miners and curious newcomers are looking for safer, more accessible ways to stay in the game. That's where ZA Miner steps in. In response to today's shifting landscape, the UK-based platform, founded in 2020, has launched a new Dogecoin cloud mining contract designed for simplicity, consistency, and low entry costs.
Known for combining green energy with user-friendly cloud mining, ZA Miner continues to make mining approachable for everyone, with no expensive gear or technical know-how needed. The new Dogecoin cloud contract fits perfectly with the growing demand for environmentally conscious mining and the increasing popularity of altcoins like Dogecoin, especially in unpredictable markets.
This latest offering allows users to tap into automated, daily DOGE rewards while minimizing complexity and risk. In a space that's constantly evolving, ZA Miner gives everyday users a smarter way to stay involved and earn, without riding the full rollercoaster of crypto trading.
Why is Dogecoin Cloud Mining Taking Over The Crypto World In 2025?
Dogecoin cloud mining is becoming the go-to choice for crypto enthusiasts in 2025, offering a strain-free route to earning daily rewards, even when market prices dip. Industry leaders are rolling out AI-powered mining packages that deliver up to 10X greater efficiency. The platforms leverage advanced algorithms to maximize hash power and reduce energy usage while boosting profits. With Dogecoin transitioning to a proof‑of‑stake model and slashing energy consumption by over 99.9%, it's now firmly ranked among the most sustainable coins to mine.
What's driving this Dogecoin cloud mining surge? First, Dogecoin's low transaction fees and fast confirmation times have turned it into a favored real-world payment option, not just a meme. Second, platforms powered by AI, green energy infrastructure, and fully automated user experiences are eliminating technical entry barriers; anyone can start mining with no hardware, no power bills, and zero management hassle.
If 2025 has taught us anything, it's that investors value stability as much as upside. Dogecoin cloud mining platforms now offer that stability, a predictable income stream that keeps rolling in rain or shine, with added environmental credibility thanks to renewable energy commitments. For those looking to stay active in crypto without riding the rollercoaster, cloud mining DOGE in 2025 is looking more like a strategic pivot than a side bet.
'At ZA Miner, we're on a mission to do more than just mine. We're here to reshape the future of cloud computing. Our goal is to create real, lasting value for our users while doing right by the planet. This isn't just innovation, it's a movement. And you're invited to be part of it,' said ZA Miner Spokesperson.
ZA Miner Cloud Mining Contracts – 2025
ZA Miner offers flexible, AI-powered Cloud mining contracts tailored to every budget, from curious newcomers to seasoned investors. Each plan pays out rewards daily and includes built-in referral commissions for extra earning potential. Plan Name Investment Duration Daily Earnings Total Return ROI (%) Referral Bonus (L1 / L2 / L3) DOGE Starter Miner $100 1 Day $2.00 $102.00 2.00% 0% / 0% / 0% DOGE Classic Miner $550 3 Days $9.96 $579.87 5.40% 7% / 3% / 1% DOGE Classic Miner $1,360 5 Days $25.02 $1,485.12 9.20% 7% / 3% / 1% DOGE Premium Miner $2,500 9 Days $47.75 $2,929.75 17.20% 7% / 3% / 1%
These cloud mining contracts include instant USDT payouts every 24 hours, allowing users to begin earning passive income immediately.
Other outstanding Features Included Across All Plans are: No need for hardware or technical setup
AI-optimized mining powered by renewable energy
Lifetime referral rewards for sharing with friends
Refer your friends and earn lifetime rewards while enjoying fully automated mining backed by sustainable technology. Ready to start? Visit the ZA Miner official Website, and claim your free $100 bonus to mine DOGE today.
How To Start Dogecoin Cloud Mining With ZA Miner
1. Sign Up & Join the Future of Mining- Create your free ZA Miner account and unlock access to cutting-edge, clean energy-powered cloud mining.
2. Pick a DOGE Mining Plan That Works for You- Select your ideal mining contract, whether you're just starting or scaling up, there's a plan to match your goals. Purchase and start earning passive income effortlessly.
3. Watch Your Earnings Grow Daily- Sit back and relax as your mining rewards are automatically credited to your account every single day, stable, secure, and hassle-free.
Join ZA Miner today and experience the future of cloud mining
Conclusion
Whether you're looking to grow your crypto portfolio or just want a steady way to earn daily income without lifting a finger, ZA Miner stands out as a top choice for 2025. With multiple ways to earn, from daily mining rewards to a rewarding two-tier referral program, global bounty campaigns, and a VIP club for loyal users. ZA Miner makes it easy to turn your time online into real returns. Fully certified by the FCA and built with an intuitive platform, it's no wonder millions around the world are already earning passively. Ready to mine smarter? Join the ZA Miner community and get started today.
Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/bb07576f-dede-470d-add7-f0e317875c7e
https://www.globenewswire.com/NewsRoom/AttachmentNg/cf696df9-4fab-4dc9-85eb-e50f60fade4d
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Ahmedabad Plane Crash
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indianapolis Star
41 minutes ago
- Indianapolis Star
Brenmiller Energy Appoints Boaz Toshav to Serve as an Independent Director on the Board
Experienced Global Investment Executive and Strategic Advisor to Support the Company's Next Phase of Growth ROSH HA'AYIN, IL / ACCESS Newswire Brenmiller Energy Ltd. ('Brenmiller', 'Brenmiller Energy', or the 'Company') (Nasdaq:BNRG), a leading global provider of Thermal Energy Storage (TES) solutions for industrial and utility customers, today announced the appointment of Mr. Boaz Toshav as an Independent Director to its Board of Directors (the 'Board'), effective immediately. Mr. Toshav previously served on the Company's Board from June 2023 until August 2024. Mr. Toshav has over 20 years of experience in investment banking, fixed income and mergers and acquisitions advisory services. He is currently President and Chairman of Rio Ave FC (Primeira Liga), a professional Portuguese football (soccer) club, and he previously served as a senior financial advisor to UK-based Nottingham Forest FC and Greece-based Olympiacos FC. Mr. Toshav also currently serves as the Chief Executive Officer of Umbrella Advisors Ltd., a boutique investment bank and financial advisory firm he founded in 2014. Mr. Toshav has also been a board member of Intelicanna Ltd. (TASE: INTL) and Getruck Ltd. since 2018 and 2021, respectively. Mr. Toshav received a Bachelor of Arts degree in Economics and Business Administration from Tel Aviv University, as well as a Master of Philosophy from Tel Aviv University. Mr. Toshav qualified as a United Kingdom Financial Services Authority certified investment advisor in 2005. 'We are honored to welcome Boaz back to our Board,' said Avi Brenmiller, Chairman and Chief Executive Officer of Brenmiller Energy. 'His proven ability to navigate financial markets, advise boards, and drive strategic partnerships will be instrumental as we enter a pivotal moment in our Company's evolution. With multiple commercial projects underway and a growing global footprint, we believe that Boaz's appointment will strengthen our governance and position us to realize significant value creation for our shareholders.' Mr. Toshav succeeds Ms. Nava Swersky Sofer, who concluded her term on the Board following six years of dedicated service. Ms. Swersky Sofer's departure was in accordance with the natural expiration of her term and was not the result of any disagreement with the Company. The Board and management extend their sincere appreciation for her strategic insight and leadership during a period of meaningful growth and transformation at Brenmiller Energy. This appointment follows Brenmiller's recent strategic milestones, including project deployments in Europe, Israel, and the United States. Notably, the European Hydrogen Bank has granted SolWinHy Cádiz S.L. (the 'SolWinHy Project') in Arcos de la Frontera, Spain, €25 million in funding. SolWinHy is a special purpose company jointly owned by leading renewable energy developers Green Enesys Group ('Green Enesys') and Viridi RE ('Viridi') to build new green hydrogen and green e-methanol projects in Europe. Green Enesys and Viridi are Brenmiller's joint venture partners in Brenmiller Europe S.L. ('Brenmiller Europe'). The Company estimates its supply of the bGen™ TES system for the SolWinHy Project to be approximately €7 million. The Company believes that its involvement with the SolWinHy Project reinforces the strength of its bGen™ technology and the Company's role in enabling renewable fuel production at scale. Brenmiller continues to expand its role as a key enabler of flexible, clean industrial heat in support of global net-zero targets. About Brenmiller Energy Ltd. Brenmiller Energy helps energy-intensive industries and power producers end their reliance on fossil fuel boilers. Brenmiller's patented bGen™ ZERO thermal battery is a modular and scalable energy storage system that turns renewable electricity into zero-emission heat. It charges using low-cost renewable electricity and discharges a continuous supply of heat on demand and according to its customers' needs. The most experienced thermal battery developer on the market, Brenmiller operates the world's only gigafactory for thermal battery production and is trusted by leading multinational energy companies. For more information visit the Company's website at and follow the company on X and LinkedIn. Forward-Looking Statements: This press release contains 'forward-looking statements' within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company uses forward-looking statements when it discusses: the Company's belief that Mr. Toshav's appointment will strengthen the Company's governance and position to realize significant value creation for shareholders; that the Company s entering a pivotal moment in its evolution; future commercial projects underway and a growing global footprint; the Company's estimates for its supply of the bGen™ TES system for the SolWinHy Project to be approximately €7 million; that the Company's involvement with the SolWinHy Project reinforces the strength of its bGen™ technology; the Company's role as a key enabler of flexible, clean industrial heat in support of global net-zero targets. Without limiting the generality of the foregoing, words such as 'plan,' 'project,' 'potential,' 'seek,' 'may,' 'will,' 'expect,' 'believe,' 'anticipate,' 'intend,' 'could,' 'estimate' or 'continue' are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this press release. Factors that may affect the Company's results include, but are not limited to: the Company's planned level of revenues and capital expenditures; risks associated with the adequacy of existing cash resources; the demand for and market acceptance of our products; impact of competitive products and prices; product development, commercialization or technological difficulties; the success or failure of negotiations; trade, legal, social and economic risks; and political, economic and military instability in the Middle East, specifically in Israel. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ended December 31, 2024 filed with the U.S. Securities and Exchange Commission ('SEC') on March 4, 2025, which is available on the SEC's website, The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
Yahoo
44 minutes ago
- Yahoo
Canadian Banc Corp. At-The-Market Equity Program Renewed
TORONTO, June 20, 2025 (GLOBE NEWSWIRE) -- Canadian Banc Corp. (the 'Company') announces it has renewed its at-the-market equity program ('ATM Program') that allows the Company to issue shares of the Company to the public from time to time at the Company's discretion, effective until July 19, 2027 unless terminated prior to such date by the Company. This ATM Program replaces the prior program established in January 2024 that has terminated. Any Class A Shares or Preferred Shares sold in the ATM Program will be sold through the Toronto Stock Exchange (the 'TSX') or any other marketplace in Canada on which the Class A Shares and Preferred Shares are listed, quoted or otherwise traded at the prevailing market price at the time of sale. Sales of Class A Shares and Preferred Shares through the ATM Program will be made pursuant to the terms of an equity distribution agreement dated June 19, 2025 with National Bank Financial Inc. (the 'Agent'). Sales of Class A Shares and Preferred Shares will be made by way of 'at-the-market distributions' as defined in National Instrument 44-102 Shelf Distributions on the TSX or on any marketplace for the Class A Shares and Preferred Shares in Canada. Since the Class A Shares and Preferred Shares will be distributed at the prevailing market prices at the time of the sale, prices may vary among purchasers during the period of distribution. The ATM Program is being offered pursuant to a prospectus supplement dated June 19, 2025 to the Company's short form base shelf prospectus dated June 18, 2025. The maximum gross proceeds from the issuance of the shares will be $350,000,000. Copies of the prospectus supplement and the short form base shelf prospectus may be obtained from your registered financial advisor using the contact information for such advisor, or from representatives of the Agent and are available on SEDAR+ at The volume and timing of distributions under the ATM Program, if any, will be determined at the Company's sole discretion. The Company intends to use the proceeds from the ATM Program in accordance with the investment objectives and investment strategies of the Company, subject to the investment restrictions of the Company. The Company invests in a portfolio of six publicly traded Canadian Banks as follows: Bank of Montreal Canadian Imperial Bank of Commerce Royal Bank of Canada The Bank of Nova Scotia National Bank of Canada The Toronto-Dominion Bank Certain statements included in this news release constitute forward-looking statements, including, but not limited to, those identified by the expressions 'expect', 'intend', 'will' and similar expressions to the extent they relate to the Company. The forward-looking statements are not historical facts but reflect the Company's current expectations regarding future results or events. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Although the Company believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and, accordingly, readers are cautioned not to place undue reliance on such statements due to the inherent uncertainty therein. The Company undertakes no obligation to update publicly or otherwise revise any forward-looking statement or information whether as a result of new information, future events or other such factors which affect this information, except as required by law. Commissions, trailing commissions, management fees and expenses all may be associated with mutual fund investments. Investors should read the prospectus before investing. Mutual funds are not guaranteed, their values change frequently and past performance may not be repeated. Please read the Company's publicly filed documents which are available at Investor Relations: 1-877-478-2372 Local: 416-304-4443 info@
Yahoo
44 minutes ago
- Yahoo
United States Diabetes Devices and Therapeutics Market Investment Opportunities Report 2025
The U.S. diabetes market is projected to grow at a CAGR of 7.2% from 2025-2029, reaching $39.33 billion. Key trends include real-time monitoring adoption, digital health integration, advanced delivery systems, and supportive regulatory frameworks. The report provides a data-centric analysis of market dynamics and opportunities. U.S. Diabetes Devices and Therapeutics Market Dublin, June 20, 2025 (GLOBE NEWSWIRE) -- The "United States Diabetes Devices and Therapeutics Market Investment Opportunities - Q2 2025 Update" report has been added to diabetes market in United States is expected to grow by 8.4% on annual basis to reach US$27.62 billion in diabetes market in the country has experienced robust growth during 2020-2024, achieving a CAGR of 9.1%. This upward trajectory is expected to continue, with the market forecast to grow at a CAGR of 7.2% during 2025-2029. By the end of 2029, the diabetes market is projected to expand from its 2024 value of USD 25.47 billion to approximately USD 39.33 billion. The U.S. diabetes devices and therapeutics market is undergoing significant shifts with real-time monitoring, digital integration, advanced delivery systems, and evolving regulatory support. These trends will intensify over the next 2-4 years, shaping clinical practices and reimbursement structures while emphasizing data integration and precise patient management. The U.S. diabetes devices and therapeutics market is characterized by a mix of established players and new entrants. Strategic partnerships, acquisitions, and the integration of digital health solutions are reshaping competitive dynamics. In the coming years, market consolidation and targeted innovation are expected to further define the competitive environment, influencing product offerings and patient management Adoption of Real-Time Glucose Monitoring U.S. healthcare providers increasingly use continuous glucose monitoring (CGM) systems to track patient glucose levels in real-time. Large healthcare networks have adopted CGM systems to support outpatient diabetes management. Recent publications indicate improvements in insurance reimbursement policies and favorable regulatory reviews. Enhanced clinical data on the reliability of CGM systems reinforces their use in routine diabetes care. Adoption is expected to increase, driven by wider coverage and enhanced device integration with electronic health records. The trend will likely intensify as more clinical studies validate the benefits of real-time monitoring in reducing long-term complications. Integrate Digital Health Solutions into Diabetes Management U.S. providers are integrating device data with telehealth platforms and remote patient monitoring systems for diabetes management. Examples include healthcare systems deploying centralized digital dashboards to monitor patient metrics remotely. Recent industry reports highlight a shift in healthcare delivery models that suggests a push toward digital transformation in chronic disease management. Insurance models increasingly support telehealth consultations and remote monitoring, aligning with broader medtech trends. The integration of digital platforms is expected to grow, promoting data-driven decision-making and enhancing care coordination. This trend will likely intensify, leading to a more efficient tracking of treatment adherence and patient outcomes. Advance Therapeutic Delivery Systems The market is witnessing the emergence of devices that support precise therapeutic delivery, such as smart insulin pens. U.S. manufacturers are introducing systems for accurate dosing and treatment adherence monitoring. Technological advancements in device miniaturization and data analytics are facilitating the development of these delivery systems. Recent healthcare publications note a rising focus on improving patient safety and treatment precision in diabetes care. Market penetration of smart delivery systems is expected to grow, influenced by evolving clinical practice guidelines and supportive reimbursement frameworks. This trend will intensify as precision therapy becomes a central focus in diabetes management. Regulatory and Reimbursement Frameworks Recent changes in FDA and CMS policies support integrating digital tools in diabetes care. Updated guidelines and expanded reimbursement criteria for digital health applications evidence these regulatory adjustments. Broader healthcare policy initiatives for cost containment and improved patient outcomes drive these regulatory changes. Publications from the past year highlight a response to the increased demand for remote monitoring and digital therapeutics. Regulatory support is expected to maintain momentum, enabling continued investment in digital health and advanced therapeutics. The framework will further intensify market adoption of compliant and data-integrated devices. Current Market ConditionsThe market comprises established manufacturers and emerging firms. A diverse portfolio of devices and therapeutics is present, ranging from established CGM systems to new smart delivery devices. Assess Key Competitors and Emerging Entrants Major companies, such as large medical device manufacturers and specialized diabetes care firms, hold significant market share. Established firms maintain comprehensive product portfolios covering both devices and therapeutics. New market entrants focus on integrating digital health solutions with diabetes management systems. These entrants bring targeted innovations, complementing the existing product mix in the U.S. market. Examine Strategic Partnerships and Corporate Activities Recent publications document acquisitions of smaller digital health companies by established device manufacturers. Strategic partnerships have been initiated between healthcare systems and technology firms to expand remote monitoring capabilities. The market shows signs of consolidation driven by competitive pressures and regulatory incentives. Collaborative efforts are aimed at enhancing integrated care delivery and data analytics capabilities. Future Competitive Dynamics Continued consolidation and strategic alliances are expected as established players seek to enhance their technological offerings. New entrants with digital health expertise will likely drive niche innovations, altering competitive positioning. Over the next 2-4 years, the competitive landscape will likely evolve with intensified competition and targeted market consolidation. Companies will increasingly leverage partnerships to improve patient data integration and therapeutic outcomes. Key Attributes: Report Attribute Details No. of Pages 50 Forecast Period 2025 - 2029 Estimated Market Value (USD) in 2025 $29.83 Billion Forecasted Market Value (USD) by 2029 $39.33 Billion Compound Annual Growth Rate 7.2% Regions Covered United States ScopeDiabetes Devices and Therapeutics Market Share by Category Diagnosis and Monitoring Devices Therapeutics Diabetes Devices and Therapeutics Market Share by Diagnosis and Monitoring Devices Blood Glucose Monitoring Devices Insulin Delivery Devices Diabetes Management and Mobile Applications Artificial Pancreas Devices Diabetes Devices and Therapeutics Market Share by Blood Glucose Monitoring Devices Self-Monitoring Blood Glucose Devices Continuous Blood Glucose Monitoring Devices Test Strips Lancets Diabetes Devices and Therapeutics Market Share by Insulin Delivery Devices Insulin Pumps Insulin Pens Insulin Syringes Diabetes Devices and Therapeutics Market Share by Therapeutics Oral Anti-Diabetic Drugs Insulin Non-Insulin Injectable Drugs Combination Drugs Diabetes Devices and Therapeutics Market Share by Oral Anti-Diabetic Drugs Alpha-Glucosidase Inhibitors DPP-4 Inhibitors SGLT-2 Inhibitors Diabetes Devices and Therapeutics Market Share by Insulin Basal or Long-Acting Bolus or Fast-Acting Traditional Human Insulin Drugs Insulin Biosimilars Diabetes Devices and Therapeutics Market Share by Non-Insulin Injectable Drugs GLP-1 Receptor Agonists Amylin Analogue Diabetes Devices and Therapeutics Market Share by Combination Drugs Combination Insulin Oral Combination Diabetes Devices and Therapeutics Market Share by Route of Administration Subcutaneous Intravenous Others Diabetes Devices and Therapeutics Market Share by Type of Diabetes Type 1 Diabetes Type 2 Diabetes Diabetes Devices and Therapeutics Market Share by Distribution Channels Online Pharmacies Hospital Pharmacies Retail Pharmacies Diabetes Devices and Therapeutics Market Share by End User Hospitals Diabetes Clinics Homecare For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment U.S. Diabetes Devices and Therapeutics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
